SG Americas Securities
IMDX

SG Americas Securities’s Insight Molecular Diagnostics IMDX Stock Holding History

SG Americas Securities’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,585
Closed -$51K – 3397
2025
Q1 		$51K Buy
+16,585
New +$44.8K ﹤0.01% 3242
2022
Q1 		– Sell
-528
Closed -$23K – 3305
2021
Q4 		$23K Sell
528
-696
-57% -$40K ﹤0.01% 3259
2021
Q3 		$87K Buy
+1,224
New +$113K ﹤0.01% 3683
2021
Q2 		– Sell
-600
Closed -$62K – 3121
2021
Q1 		$62K Buy
+600
New +$57K ﹤0.01% 3144
2020
Q3 		– Sell
-1,177
Closed -$45K – 3222
2020
Q2 		$45K Buy
+1,177
New +$60.8K ﹤0.01% 3548

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities's IMDX Position: Q2 2025 in Review

SG Americas Securities sold out of Insight Molecular Diagnostics (IMDX) in Q2 2025, closing a stake of 16,585 shares — an estimated $51K sold.

SG Americas Securities first reported a position in IMDX in Q2 2020 and held it in 5 quarters. The position peaked at $87K in Q3 2021. 30 funds tracked by Wall St. Rank hold IMDX as of Q2 2025.

  • SG Americas Securities reported no remaining Insight Molecular Diagnostics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 16,585 Insight Molecular Diagnostics shares in Q2 2025, an estimated $51K.
  • SG Americas Securities first reported a position in Insight Molecular Diagnostics in Q2 2020 and held it in 5 quarters.
  • SG Americas Securities's Insight Molecular Diagnostics position peaked at $87K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.